ALFA Finder| Value | ₹65.00 Cr |
|---|
BSE filing, NSE: ASPIRA. Summary written from the filing by ALFA Finder's alert engine.
Aspira Pathlab & Diagnostics Ltd: key numbers
- Share price
- ₹126.95
- Market cap
- ₹130.7 Cr
- Revenue (annual)
- ₹24.98 Cr
- Net profit (annual)
- ₹0.05 Cr
- P/E (TTM)
- -37.9×Sector 54.4×
- Promoter holding
- 46.65%+0.07% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Aspira Pathlab & Diagnostics Ltd
All →Aspira Pathlab & Diagnostics Q2 FY27 Results: Net Loss of ₹1.2 Cr
Aspira Pathlab & Diagnostics Ltd reported revenue from operations of ₹6.3 Cr (-22.2% YoY) and a net loss of ₹1.2 Cr for Q2 FY27.
- Key figure
- Net loss ₹1.2 Cr
Aspira Pathlab & Diagnostics Board Meeting Date
Aspira Pathlab & Diagnostics will hold a board meeting on November 6, 2026 to consider unaudited standalone results for the quarter and half year ended September 30, 2026. The trading window stays closed until 48 hours after the results.
Aspira Pathlab & Diagnostics Other Announcement
Aspira Pathlab & Diagnostics Ltd has filed its quarterly shareholding pattern for the quarter ended September 30, 2026, in compliance with SEBI Listing Regulations.
Aspira Pathlab & Diagnostics Promoter Buying: ₹0.02 Cr
Promoter Jay Arvind Bhanushali acquired 1,424 equity shares of Aspira Pathlab & Diagnostics Ltd via market purchase. The transaction is valued at ₹0.02 Crore.
- Value
- ₹0.02 Cr
- Promoter stake change
- +0.01%
Aspira Pathlab & Diagnostics Promoter Buying
Promoter Jay Arvind Bhanushali acquired 1,424 shares of Aspira Pathlab & Diagnostics Ltd via the open market. This transaction increased the promoter's stake from 7.27% to 7.28%.
- Execution
- 17-09-2026 to 24-09-2026
- Promoter stake change
- +0.01%
Aspira Pathlab & Diagnostics Annual General Meeting
Aspira Pathlab & Diagnostics held its 53rd Annual General Meeting on September 25, 2026, where members deliberated on financial statements and various directorial appointments.
Other fund raise announcements
All →Virinchi Fund Raise of ₹30 Cr
Virinchi's board approved a Rs 30 Crore preferential issue of 2 crore convertible warrants at Rs 15 each. Subject to EGM approval, allottees include promoter Viswanath Kompella.
- Value
- ₹30.00 Cr
- Execution
- Warrant tenure not exceeding 18 months from allotment
IIFL Finance Fund Raise of ₹6,414 Cr
IIFL Finance's board approved a preferential issue of convertible preference shares and warrants worth Rs.6,414.20 Crore. Shareholder approval is needed at a 4 December EGM.
- Value
- ₹6,414 Cr
Bajaj Finance Fund Raise of ₹5,800 Cr
Bajaj Finance's special committee approved issuing 5.74 crore warrants to promoter Bajaj Finserv at ₹1,010 each. The issue raises about ₹5,800 crore.
- Value
- ₹5,800 Cr
Cholamandalam Investment & Finance Company Fund Raise of ₹5,000 Cr
Cholamandalam Investment sent shareholders a postal ballot notice seeking approval for a Rs 5,000 crore QIP. E-voting runs November 10 to December 9, 2026.
- Value
- ₹5,000 Cr
- Execution
- Allotment to be completed within 365 days of shareholder approval
HB Leasing & Finance Co Fund Raise
HB Leasing's board discussed fund-raising options on November 9, 2026, including equity and preference shares. No quantum or pricing is decided; advisers will be consulted.
United Van Der Horst Fund Raise of ₹2 Cr
United Van Der Horst's board approved a preferential issue of 62.50 lakh equity shares at Rs.32 each, raising about Rs.2.00 Crore. The record date is set for 30 November 2026.
- Value
- ₹2.00 Cr